The long-term goal of the proposed studies is to exploit existing technologies to generate comprehensive profiles of molecular alteration in ovarian cancers in order to identify clinically relevant molecular tumor signatures. Although the currently employed morphology-based ovarian tumor classification system has laid the groundwork for viewing ovarian cancer as several overlapping, but distinct disease entities, the existing scheme has significant limitations in its ability to allow prediction of the clinical course of an individual ovarian cancer patient. The major thrust of this proposal is to generate comprehensive molecular profiles of the most common histologic type of ovarian carcinoma, i.e., serious carcinoma, and to provide a basis for the identification of molecular markers of serious carcinoma with potential clinical relevance (Aim 1). The studies will deliberately focus on one histologic type in order to increase the likelihood of identifying biomarkers on which to base new and more informative tumor classification schemes. In the course of these studies, a series of related questions pertaining to ovarian cancer biology and tumor biology in general, will also be addressed (Aim 2).
Aim 1 : To define protein and gene expression profiles in 250-300 serous ovarian carcinomas, in order to identify molecular markers that distinguish clinically or biologically distinct subgroups of patients, including those with early versus advanced stage disease, low versus high grade tumors, and those with survival versus death.
Aim 2 : To define data on protein and gene expression patterns in ovarian carcinomas and other common tumor types (colorectal and lung carcinomas) to pursue the following objectives: 1) To identify specific patterns of gene/protein expression or genomic alteration that characterize serous versus other major types of ovarian carcinoma (mucinous, endometrioid, and clear cell) 2) To identify markers unique to ovarian carcinomas that can be used to distinguish them from normal ovarian tissues as well as tumors from other primary sites (specifically colorectal and lung cancers) 3) To identify novel molecular markers of ovarian, serous carcinomas with which to evaluate serous cystadenomas and serous tumors of low malignant potential as candidate serous carcinoma precursor lesions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA084953-04
Application #
6587843
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-04-26
Project End
2003-03-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Silvers, Amy L; Lin, Lin; Bass, Adam J et al. (2010) Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 16:2009-21
Guo, Nancy L; Wan, Ying-Wooi; Tosun, Kursad et al. (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14:8213-20
Ding, Li; Getz, Gad; Wheeler, David A et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-75
Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma; Shedden, Kerby; Taylor, Jeremy M G et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822-7
Wu, Rong; Hendrix-Lucas, Neali; Kuick, Rork et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321-33
Hong, Su-Hyung; Misek, David E; Wang, Hong et al. (2006) Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomark Insights 1:175-183
Hendrix, Neali D; Wu, Rong; Kuick, Rork et al. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66:1354-62
Levin, Albert M; Ghosh, Debashis; Cho, Kathleen R et al. (2005) A model-based scan statistic for identifying extreme chromosomal regions of gene expression in human tumors. Bioinformatics 21:2867-74
Shedden, Kerby A; Kshirsagar, Malti P; Schwartz, Donald R et al. (2005) Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 11:2123-31
Hinoi, Takao; Gesina, Galina; Akyol, Aytekin et al. (2005) CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology 128:946-61

Showing the most recent 10 out of 23 publications